1620 Investment Advisors’s Intellia Therapeutics NTLA Stock Holding History

1620 Investment Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22K	Hold	1,300	–	–	0.01%	410
2026 Q1	$16.7K	Hold	1,300	–	–	0.01%	406
2025 Q4	$11.7K	Hold	1,300	–	–	0.01%	444
2025 Q3	$22.5K	Hold	1,300	–	–	0.02%	373
2025 Q2	$12.2K	Buy	+1,300	New	+$10.7K	0.01%	441

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

1620 Investment Advisors's NTLA Position: Q2 2026 in Review

1620 Investment Advisors held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 1,300 shares worth $22K. The position accounts for 0.01% of the portfolio, ranked #410.

1620 Investment Advisors first reported a position in NTLA in Q2 2025 and has held it in 5 quarters since. The position peaked at $22.5K in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

1620 Investment Advisors held 1,300 shares of Intellia Therapeutics worth $22K as of Q2 2026.
1620 Investment Advisors left its Intellia Therapeutics share count unchanged in Q2 2026.
Intellia Therapeutics made up 0.01% of 1620 Investment Advisors's portfolio in Q2 2026, its #410 holding.
1620 Investment Advisors first reported a position in Intellia Therapeutics in Q2 2025 and has held it in 5 quarters since.
1620 Investment Advisors's Intellia Therapeutics position peaked at $22.5K in Q3 2025.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.